#United States #Anixa Biosciences #San Jose #Patent #Breast Cancer Vaccine

Anixa Biosciences' New Patent Achievement

Anixa Biosciences, Inc., a pioneering biotechnology firm, has achieved a significant milestone by securing a Chinese patent for its innovative breast cancer vaccine technology. This patent, issued by the Chinese National Intellectual Property Administration (CNIPA), ensures legal protection for Anixa's groundbreaking vaccine until the year 2040, bolstering the company's intellectual property portfolio across key global markets with high incidences of breast cancer.

The patented breast cancer vaccine has been developed in collaboration with the Cleveland Clinic, and represents a novel approach to combating this prevalent form of cancer. Unlike traditional vaccines, Anixa's formulation targets human α-lactalbumin, a protein produced during lactation that is irregularly expressed in various breast cancer cells. By immunizing against this 'retired' protein, the vaccine aims to activate the immune system to thwart tumor growth without damaging healthy tissue, marking a pivotal shift in preventive techniques against the disease.

Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, highlighted the importance of this newly issued patent, emphasizing it as a testament to the uniqueness and promise held by the breast cancer vaccine. He stated, "As we continue advancing clinical development in the U.S., this patent further strengthens our ability to pursue strategic global opportunities in regions with a high incidence of breast cancer."

Anixa's commitment to expanding its research and development initiatives is reflected in its ongoing Phase 1 clinical trial, which has just concluded. Detailed results from this trial are scheduled to be presented at the prestigious San Antonio Breast Cancer Symposium on December 11, 2025, marking another significant step in the drug's development lifecycle.

Anixa's extensive pipeline also includes an ovarian cancer immunotherapy program, developed in partnership with the renowned Moffitt Cancer Center. This initiative involves a cutting-edge variant of CAR-T therapy known as chimeric endocrine receptor-T cell (CER-T) technology. CER-T therapy distinguishes itself from conventional treatments by specifically employing the natural hormone FSH to target tumor cells, rather than relying solely on antibody fragments, underscoring Anixa's innovative approach to cancer treatment.

In addition to breast and ovarian cancer vaccines, Anixa is engaged in developing therapeutics to tackle several challenging malignancies, such as those affecting the lung, colon, and prostate. Their vaccine technologies are crafted to target 'retired' proteins associated with these cancers, showcasing the versatility of their research capabilities.

Anixa operates under a unique business model, forming strategic partnerships with leading research institutions to advance its biotechnological innovations. This collaborative strategy allows the company to explore and integrate emerging technologies in complementary fields, paving the way for further advancements in cancer treatment and prevention.

In conclusion, Anixa Biosciences is positioning itself as a leader in the field of cancer immunotherapy with the issuance of this significant patent in China, reflecting its dedication to leveraging its intellectual property for the betterment of global health outcomes. Through ongoing clinical trials and innovative collaborations, Anixa is set on a path to revolutionize how breast cancer and other malignancies are treated, demonstrating the power of science in the fight against cancer.